The role of adiponectin in endothelial dysfunction and hypertension

Current Hypertension Reports

Volumn 16, Issue 8, 2014, Pages

  Rojas, Edward ^a,f   Rodríguez Molina, Daloha ^a   Bolli, Peter ^b   Israili, Zafar H ^c   Faría, Judith ^a   Fidilio, Enzamaría ^d   Bermúdez, Valmore ^a   Velasco, Manuel ^e  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b MCMASTER UNIVERSITY   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Military Hospital of Maracaibo   (Venezuela)

^e UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^f UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Adiponectin; Endothelial dysfuction; Hypertension; Nitric oxide; Obesity; Renin angiotensin aldosterone system

Indexed keywords

5' ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOOXYGENASE 2; NITRIC OXIDE; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

ADIPOSE TISSUE; ANTIHYPERTENSIVE THERAPY; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL MIGRATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HYPERTENSION; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; NONHUMAN; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; BLOOD PRESSURE; METABOLISM; PHYSIOLOGY;

ADIPONECTIN; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; INSULIN RESISTANCE;

EID: 84902037717     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0463-7     Document Type: Article

References (84)

1. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403-18.
3. Quinn R, Zarnke K, Rabi D, et al. The 2014 Canadian Hypertension Education Program (CHEP) recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 2014;30(5):485-501.
4. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(1):S14-80.
5. Bays HE. "Sick fat", metabolic disease, and atherosclerosis. Am J Med. 2009;122(1):S26-37.
6. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, American Heart Association, National Heart Lung and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-8. (Pubitemid 38133916)
7. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey NHANES III, National Cholesterol Education Program NCEP. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210-4. (Pubitemid 36523358)
8. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448-54. (Pubitemid 40396812)
9. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Feder a tion Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
10. Simmons RK, Alberti KGMM, Gale EAM, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2009;53(4):600-5.
11. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-9.
12. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221(2):286-9. (Pubitemid 26136463)
13. Elissondo N, Gómez-Rosso L,Maidana P, Brites F. Adiponectin: an adipocytokine with multiple protective functions. Acta Bioquim Clin Latinoam. 2008;42(1):17-33.
14. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(1):29-33. (Pubitemid 38082408)
15. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie. 2004;86(11):779-84. (Pubitemid 39602756)
16. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-5. (Pubitemid 32472900)
17. Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, et al. Organization of the gene for gelatin-binding protein (GBP28). Gene. 1999;229(1-2):67-73. (Pubitemid 29148308)
18. Fumeron F, Aubert R, Siddiq A, et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes. 2004;53(4):1150-7. (Pubitemid 38436631)
19. Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord. 2000;24(7):861-8. (Pubitemid 30449921)
20. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005;46(7):1369-79. (Pubitemid 43109800)
21. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci. 2006;110(3):267.
22. Punyadeera C, Zorenc AHG, Koopman R, McAinch AJ, Smit E, Manders R, et al. The effects of exercise and adipose tissue lipolysis on plasma adiponectin concentration and adiponectin receptor expression in human skeletal muscle. Eur J Endocrinol. 2005;152(3):427-36. (Pubitemid 40439496)
23. Fang X, Sweeney G. Mechanisms regulating energymetabolism by adiponectin in obesity and diabetes. Biochem Soc Trans. 2006;34(Pt 5):798-801. (Pubitemid 44796424)
24. Suzuki S, Wilson-Kubalek EM, Wert D, Tsao T-S, Lee DH. The oligomeric structure of high molecular weight adiponectin. FEBS Lett. 2007;581(5):809-14. (Pubitemid 46282708)
25. Ekmekçi H, Ekmekçi OB. The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thromb Hemost. 2006;12(2):163-8. (Pubitemid 44400857)
26. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008;51(1):8-14. (Pubitemid 350307092)
27. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278(41):40352-63. (Pubitemid 37248604)
28. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006;55(1):249-59. (Pubitemid 43343322)
29. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26(8):2442-50. (Pubitemid 36993340)
30. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006;8(3):264-80.
31. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabet ic metabolic effects. Nature. 2003;423(6941):762-9. (Pubitemid 36735700)
32. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-51. (Pubitemid 40686653)
33. Siitonen N, Pulkkinen L, Mager U, et al. Association of sequence variations in the gene encoding adiponectin receptor 1 (ADIPOR1) with body size and insulin levels. The Finnish Diabetes Prevention Study. Diabetologia. 2006;49(8):1795-805. (Pubitemid 44025034)
34. Kharroubi I, Rasschaert J, Eizirik DL, Cnop M. Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun. 2006;312(4):1118-22.
35. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-92. (Pubitemid 44033298)
36. •• Bermúdez VJ, Rojas E, Toledo A, et al. Single-nucleotide polymorphisms in Adiponectin, AdipoR1, and AdipoR2 Genes: insulin resistance and type 2 diabetes mellitus candidate genes. Am J Ther. 2013;20(4):414-21. This review of the literature thoroughly explains the biological and genetic structures of adiponectin and its receptors, particularly in the context of insulin resistance and type 2 diabetes mellitus.
37. Staiger H, Kaltenbach S, Staiger K, et al. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes. 2004;53(9):2195-201. (Pubitemid 39145571)
38. Gu W, Li X, Liu C, et al. Globular adiponectin augments insulin secretion from pancreatic islet beta cells at high glucose concentrations. Endocrine. 2006;30(2):217-21. (Pubitemid 46340525)
39. Hopkins TA, Ouchi N, Shibata R,Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74(1):11-8. (Pubitemid 46366942)
40. Bays HE, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Futur Cardiol. 2005;1(1):39-59.
41. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296-301.
42. Ouchi NN, Kihara SS, Arita YY, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6.
43. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003;16(1):72-5. (Pubitemid 36078595)
44. Huang K-C, Chen C-L, Chuang L-M, Ho S-R, Tai T-Y, Yang W-S. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab. 2003;88(9):4130-4. (Pubitemid 37153709)
45. Yilmaz MI, Sonmez A, Kilic S, Celik T, Bingol N, Pinar M, et al. The association of plasma adiponectin levels with hypertensive retinopathy. Eur J Endocrinol. 2005;152(2):233-40. (Pubitemid 40309570)
46. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43(6):1318-23. (Pubitemid 38691756)
47. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42(1):76-81. (Pubitemid 36842239)
48. Nowak Ł, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2005;18(11):1470-5. (Pubitemid 41566678)
49. Tomiyama H, Motobe K, Zaydun G, Koji Y, Yambe M, Arai T, et al. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan. Am J Hypertens. 2005;18(2 Pt 1):178-82. (Pubitemid 40332546)
50. Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens. 1999;21(1-2):167-79. (Pubitemid 29084631)
51. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007;12(2):147-53. (Pubitemid 46426854)
52. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002;25(6):971-6. (Pubitemid 41110480)
53. Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27-32.
54. Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K. Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res. 2003;26(9):705-10. (Pubitemid 37258657)
55. Andrikou I, Tsioufis C, Bafakis I, Kintis K, Almyroudi M, Syrseloudis D, et al. Non-dipping pattern is related to hypoadiponectinemia and increased arterial stiffness in essential hypertensive subjects. J Hypertens. 2011;29:e447. Monday Posters: Poster Session: Poster Session 31: Blood Pressure Measurement.
56. • Baden MY, Yamada Y, Takahi Y, et al. Association of adiponectin with blood pressure in healthy people. Clin Endocrinol (Oxf). 2013;78(2):226-31. This report analyzes the relationship between adiponectin and hypertension in normotensive subjects, demonstrating an inverse association that is present even in the absence of high blood pressure disease.
57. Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yoshida D, et al. Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J. 2004;68(12):1194-8. (Pubitemid 40018867)
58. Fontana V, de Faria APC, Oliveira-Paula GH, Silva PS, Biagi C, Tanus-Santos JE, Moreno H. Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension. Basic Clin Pharmacol Toxicol. 2014; Jan 15. doi:10.1111/bcpt.12195.
59. Inoue Y, Kakuma T, Nonaka Y, et al. Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels. Clin Exp Hypertens. 2010;32(1):21-8.
60. Ohashi K, Kihara S, Ouchi N, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47(6):1108-16. (Pubitemid 44289168)
61. Ramsay JE, Jamieson N, Greer IA, Sattar N. Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension. 2003;42(5):891-4. (Pubitemid 37413726)
62. Mazaki-Tovi S, Kanety H, Pariente C, et al. Maternal serum adiponectin levels during human pregnancy. J Perinatol. 2007;27(2):77-81. (Pubitemid 46195903)
63. Shinohara K, Wakatsuki A, Watanabe K, Ikenoue N, Fukaya T. Plasma adiponectin concentrations in women with preeclampsia. Hypertension. 2004;43(4):e17. author reply e17.
64. Kim C-H, Pennisi P, Zhao H, Yakar S, Kaufman JB, Iganaki K, et al. MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am J Physiol Endocrinol Metab. 2006;291(2):E298-305. (Pubitemid 44035289)
65. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, et al. Association of the T-G polymorphismin adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes. 2002;51(1):37-41. (Pubitemid 34517977)
66. Zacharova J, Chiasson J-L, Laakso M, STOP-NIDDM Study Group. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes. 2005;54(3):893-9. (Pubitemid 40322096)
67. Menzaghi C, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer PE, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes. 2002;51(7):2306-12. (Pubitemid 34729040)
68. Ukkola O, Ravussin E, Jacobson P, Sjöström L, Bouchard C. Mutations in the adiponectin gene in lean and obese subjects from the Swedish obese subjects cohort. Metab Clin Exp. 2003;52(7):881-4. (Pubitemid 36949552)
69. Yang W-S, Chuang L-M. Human genetics of adiponectin in the metabolic syndrome. J Mol Med. 2006;84(2):112-21. (Pubitemid 43201250)
70. Chow W-S, Cheung BMY, Tso AWK, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007;49(6):1455-61. (Pubitemid 46809394)
71. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-7. (Pubitemid 38489895)
72. Celoria BMJ, Genelhu VA, Pimentel Duarte SF, Delfraro PAS, Francischetti EA. Hypoadiponectinemia is associated with prehypertension in obese individuals of multiethnic origin. Clin Cardiol. 2010;33(6):E61-5.
73. Hanley AJG, Bowden D, Wagenknecht LE, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab. 2007;92(7):2665-71. (Pubitemid 47037374)
74. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003;88(7):3236-40. (Pubitemid 36877499)
75. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, et al. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75(4):719-27. (Pubitemid 47243720)
76. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42(3):231-4. (Pubitemid 37093465)
77. Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens. 2011;24(3):263-9.
78. Ouedraogo RR, Gong YY, Berzins BB, Wu XX, Mahadev KK, Hough KK, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007;117(6):1718-26.
79. Tan KCBK, Xu AA, Chow WSW, Lam MCWM, Ai VHGV, Tam SCFS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004;89(2):765-9.
80. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399(6736):597-601.
81. Hattori YY, Suzuki MM, Hattori SS, Kasai KK. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia. 2003;46(11):1543-9.
82. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci. 1991;88(7):2692-6. (Pubitemid 21916484)
83. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007;292(4):H1655- 63. (Pubitemid 46572387)
84. •• Funahashi T, Matsuzawa Y. Adiponectin and the cardiometabolic syndrome: an epidemiological perspective. Best Pract Res Clin Endocrinol Metab. 2014;28(1):93-106. This review of the literature structurally reports the relationship between adiponectin and each of the metabolic syndrome components, as well as other diseases such as obstructive sleep apnea-hypopnea syndrome (OSAHS), hepatic steatosis and fibrosis, cancer, and other disorders with paradoxically high levels of adiponectin.